Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Selexipag Pediatric vs Adult Tablets in Healthy Males
NCT02745860Phase 1Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jun 2016
- Primary completion
- Jun 2016
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of selexipag in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Area under plasma concentration-time curve from time zero to infinity at 72 hours and Maximum plasma concentration at 72 hours. Started Jun 2016; status: completed.
02
Drugs
selexipag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02745860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02745860.